Mental Health Clinics in Port Isabel, TX Accepting Medicare
3 Mental Health Clinics found. Showing 1 - 3
 Madre Bay Consulting And Psychological Services, Pllc Psychologist Medicare: Not Enrolled in Medicare Practice Location: 215 E Queen Isabella Blvd Ste 102b, Port Isabel, TX 78578 Phone: 956-299-6107 Fax: 956-299-6107 |
Pinkerman Psychological Services, Pllc Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 413 E Railroad Ave, Port Isabel, TX 78578 Phone: 956-451-8113 |
Cascos Counseling Institute, Pllc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 413 E Railroad Ave, Port Isabel, TX 78578 Phone: 956-451-8113 |
News Archive
MACROD2 gene may explain why some breast cancers are resistant to tamoxifen
After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are resistant to tamoxifen, a widely used hormone treatment generally used after surgery, radiation and other chemotherapy.
UCLA researchers develop new combination therapy to activate immune response against glioblastoma
UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors.
GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD
Today GenVec, Inc. announced a new contract with the Department of Homeland Security to continue the development of adenovector-based vaccines against foot-and-mouth disease (FMD) based on research and development done in collaboration with USDA-ARS and DHS S&T scientists at the Plum Island Animal Disease Center.
FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 7 days ago